证券之星消息，10月22日南向资金增持31.65万股复星医药（02196.HK）。近5个交易日中，获南向资金 减持的有2天，累计净减持29.6万股。近20个交易日中，获南向资金减持的有12天，累计净减持1651.55 万股。截至目前，南向资金持有复星医药（02196.HK）3.06亿股，占公司已发行普通股的55.51%。 上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经 营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要 从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上 线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其 他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025- ...

证券之星消息，10月15日南向资金减持70.4万股复星医药（02196.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持434.05万股。近20个交易日中，获南向资金减持的有13天，累计净减持 1981.17万股。截至目前，南向资金持有复星医药（02196.HK）3.07亿股，占公司已发行普通股的 55.57%。 上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经 营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要 从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上 线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其 他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 202 ...

Group 1 - The core point of the news is that southbound funds have been reducing their holdings in Fosun Pharma (02196.HK), with a total net reduction of 911.55 million shares over the last five trading days and 2,214.17 million shares over the last twenty trading days [1][2] - As of October 13, 2025, southbound funds hold 310 million shares of Fosun Pharma, accounting for 56.07% of the company's total issued ordinary shares [1][2] - The trading data indicates fluctuations in shareholding, with a decrease of 119.3 million shares on October 13, 2025, representing a change of -0.38% [2] Group 2 - Fosun Pharma operates in five segments: pharmaceutical, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other pharmaceutical-related businesses [2] - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccines, while the medical devices segment includes molecular diagnostics and medical beauty devices [2] - The company's products primarily target treatment areas such as oncology, immunology, and central nervous system disorders [2]

Core Viewpoint - Southbound funds reduced their holdings in Fosun Pharma (02196.HK) by 12,500 shares on September 19, 2025, indicating a trend of net selling over the past 20 trading days [1] Group 1: Shareholding Changes - In the last 5 trading days, there were 3 days of net buying by southbound funds, totaling an increase of 744,400 shares [1] - Over the past 20 trading days, southbound funds have reduced their holdings on 15 days, with a total net reduction of 25,690,700 shares [1] - As of now, southbound funds hold 321 million shares of Fosun Pharma, accounting for 58.07% of the company's total issued ordinary shares [1] Group 2: Trading Data - On September 19, 2025, the total number of shares held was 321 million, with a change of -12,500 shares, reflecting a change of -0.00% [2] - On September 18, 2025, the total number of shares held was 321 million, with an increase of 1,714,000 shares, reflecting a change of 0.54% [2] - On September 17, 2025, the total number of shares held was 261 million, with a decrease of 4,086,000 shares, reflecting a change of -1.27% [2] Group 3: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five segments [2] - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccines [2] - The medical devices and diagnostics segment is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2]

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Fosun Pharma (02196.HK) by 1.714 million shares on September 18, 2025, while experiencing a net reduction of 1.861 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings in Fosun Pharma for 15 days, resulting in a total net reduction of 26.2152 million shares [1] - As of now, southbound funds hold 321 million shares of Fosun Pharma, accounting for 58.07% of the company's total issued ordinary shares [1] Group 2 - The total number of shares held by southbound funds on September 18, 2025, was 321 million, reflecting a change of 1.714 million shares, or an increase of 0.54% [2] - On September 17, 2025, the total shares held decreased by 4.086 million shares, representing a decline of 1.27% [2] - Fosun Pharma operates in five segments, including pharmaceuticals, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other pharmaceutical-related businesses [2]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Fosun Pharma (02196.HK) by 4.086 million shares on September 17, 2025, marking a decrease of 1.27% in their total holdings [1][2] - Over the past five trading days, southbound funds have reduced their holdings on three occasions, resulting in a cumulative net reduction of 2.5952 million shares [1][2] - In the last twenty trading days, there have been fifteen days of reductions, with a total net decrease of 27.6502 million shares [1][2] Group 2 - As of now, southbound funds hold 319 million shares of Fosun Pharma, which accounts for 57.76% of the company's total issued ordinary shares [1][2] - Fosun Pharma operates in five segments, including pharmaceuticals, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other pharmaceutical-related businesses [2] - The company's products primarily target treatment areas such as oncology, immunology, and central nervous system disorders [2]